文献速递妇科

prexasertib(LY2606368)治疗铂耐药或铂难治性复发性卵巢癌的2期研究

A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2022-09-30

这项2期多中心试验将169例卵巢癌患者分为4个队列,评估CHK1抑制剂prexasertib单药治疗的客观缓解率与安全性。铂耐药患者客观缓解率为12.1%,铂难治患者为6.9%;铂耐药患者疾病控制率为37.1%,铂难治患者为31.0%。常见治疗相关不良事件包括血小板减少、中性粒细胞减少、疲乏、恶心和贫血。

要点

  • 铂耐药患者(队列1–3)客观缓解率为12.1%,铂难治患者为6.9%。
  • 铂耐药患者疾病控制率为37.1%且各队列一致,铂难治患者为31.0%。
  • 常见治疗相关不良事件为血小板减少、中性粒细胞减少、疲乏、恶心和贫血。

核心结论

  • prexasertib在部分复发性卵巢癌患者中显示出持久的单药活性,与临床特征、BRCA状态或既往治疗(包括PARP抑制剂)无关。
  • 缓解者与非缓解者之间未发现与基因组改变的明显相关性,强调需要替代的生物标志物方法来识别缓解者。

研究设计与样本

  • 2期多中心试验(NCT03414047),纳入卵巢癌患者N=169,分为4个队列。
  • 队列1:铂耐药、BRCA野生型、既往治疗≥3线;队列2:铂耐药、BRCA野生型、既往治疗<3线;队列3:铂耐药、BRCA突变、既往接受PARP抑制剂治疗;队列4:铂难治、BRCA突变或BRCA野生型、既往治疗线数不限。
  • 主要终点为客观缓解率(ORR),次要终点包括疾病控制率(DCR)和安全性。
  • 对肿瘤活检DNA进行测序以识别生物标志物。

主要发现

  • 铂耐药患者(队列1–3)的ORR为12.1%,铂难治患者为6.9%。
  • 铂耐药患者DCR为37.1%,且各队列一致;铂难治患者DCR为31.0%。
  • 与prexasertib作用机制一致,最常见的全级别治疗相关不良事件包括血小板减少、中性粒细胞减少、疲乏、恶心和贫血。
  • 缓解者与非缓解者之间未发现与基因组改变的明显相关性。

关键数值与推荐

  • 铂耐药患者(队列1–3)ORR为12.1%。
  • 铂难治患者ORR为6.9%。
  • 铂耐药患者DCR为37.1%,各队列一致。
  • 铂难治患者DCR为31.0%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: High-grade serous ovarian cancer, the most frequent type of ovarian cancer, has a poor prognosis and novel treatments are needed for patients with platinum resistant/refractory disease. New therapeutic strategies targeting cell cycle checkpoints, including CHK1 inhibition with prexasertib, may help improve clinical response and overcome resistance. METHODS: Patients with ovarian cancer (N = 169) were assigned to 4 cohorts as part of the Phase 2 multicenter trial (NCT03414047): Cohort 1: platinum resistant, BRCA-wildtype with ≥3 lines prior therapy; Cohort 2: platinum resistant BRCA-wildtype with <3 lines prior therapy; Cohort 3: platinum resistant, BRCA-mutated with prior PARP inhibitor therapy; Cohort 4: platinum refractory, BRCA-mutated, or BRCA-wildtype with any number of prior therapy lines. The primary endpoint was objective response rate (ORR) and secondary endpoints included disease control rate (DCR), and safety. DNA from tumor biopsies was sequenced to identify biomarkers. RESULTS: The ORR in platinum resistant patients (Cohorts 1--3) was 12.1%, and 6.9% in platinum refractory patients. In platinum resistant patients, DCR was 37.1%, and consistent across cohorts. In platinum refractory patients, DCR was 31.0%. Consistent with the prexasertib mechanism of action, the most common treatment related adverse events of all grades included thrombocytopenia, neutropenia, fatigue, nausea, and anemia. CONCLUSIONS: Prexasertib demonstrated durable single agent activity in a subset of patients with recurrent ovarian cancer regardless of clinical characteristics, BRCA status, or prior therapies, including PARPi. There was no obvious correlation with genomic alterations in responders vs non-responders, emphasizing the need for alternative biomarker approaches for responder identification.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Konstantinopoulos PA, Lee JM, Gao B, et al. A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer. Gynecol Oncol. 2022. PMID: 36192237. doi:10.1016/j.ygyno.2022.09.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。